A National, Multicenter, Prospective, Interventional, Open-label, Single-arm, 24-Week Phase IV Study to Evaluate the Effectiveness and Safety of Initiation and Titration of Insulin Glargine U300 in Insulin-naive Patients With T2DM Inadequately Controlled on OAD Treatment in Turkey

Trial Profile

A National, Multicenter, Prospective, Interventional, Open-label, Single-arm, 24-Week Phase IV Study to Evaluate the Effectiveness and Safety of Initiation and Titration of Insulin Glargine U300 in Insulin-naive Patients With T2DM Inadequately Controlled on OAD Treatment in Turkey

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 10 Jul 2017

At a glance

  • Drugs Insulin glargine (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Acronyms EASE
  • Sponsors Sanofi
  • Most Recent Events

    • 04 Jul 2017 Planned End Date changed from 31 Dec 2017 to 1 Dec 2017.
    • 04 Jul 2017 Planned primary completion date changed from 31 Dec 2017 to 1 Dec 2017.
    • 04 Jul 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top